PYGM and NTAQ1

Number of citations of the paper that reports this interaction (PubMedID 25416956)
381

Data Source:
BioGRID (two hybrid)

		PYGM	NTAQ1
Description		glycogen phosphorylase, muscle associated	N-terminal glutamine amidase 1
Image
GO Annotations	Cellular Component	Cytoplasm Cytosol Extracellular Exosome	Nucleus Cytosol
	Molecular Function	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity	Protein Binding Protein-N-terminal Asparagine Amidohydrolase Activity Protein-N-terminal Glutamine Amidohydrolase Activity
	Biological Process	Glycogen Metabolic Process Glycogen Catabolic Process	Cellular Protein Modification Process
Pathways		Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)
Drugs		Pyridoxal Phosphate Beta-D-Glucopyranose Spirohydantoin 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione alpha-D-glucose 6-phosphate 1-N-Acetyl-Beta-D-Glucosamine Fluoro-Phosphite Ion Beta-D-Glucose 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione Nojirimycine Tetrazole Indirubin-5-Sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-Acetyl-N'-Beta-D-Glucopyranosyl Urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione Alvocidib 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose N-(8,9,10-Trihydroxy-7-Hydroxymethyl-2,4-Dioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Dec-3-Yl-Acetamide 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N'-Pyridoxyl-Lysine-5'-Monophosphate Heptulose-2-Phosphate N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea Dexfosfoserine 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
Diseases		Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GWAS		Urate levels ( 21768215)
Interacting Genes		8 interacting genes: ERO1B NTAQ1 PPP1CA PPP2CA PRKAB2 S100A1 TOP1 TRIM63	106 interacting genes: ACTB ACTG1 AMOT AMOTL2 APIP ASL BLMH BLOC1S6 C1orf50 CAPN3 CBFA2T2 CBS CBY2 CCDC102B CCDC184 CDA CDR2 CEP55 COG6 COIL CRYAA CTBP1 CTH DAB1 DCTPP1 DHPS DNM2 EDARADD EIF2B1 ETV6 FTH1 GAS7 GMCL1 GMDS GNMT GOLGA2 HPRT1 HSD17B14 IKZF3 JAKMIP2 JUP KASH5 KCNH1 KCTD1 KLHL12 KRT31 KRTAP10-5 KRTAP10-7 KRTAP4-2 KRTAP5-9 KRTAP9-2 KRTAP9-4 LMNA LNX2 LONRF1 LZTFL1 LZTS2 MAGEA11 MARCHF10 MDFI MIF MIOS MTUS2 NAGK NCOA5 NECAB2 NME1 NPL NT5C1A NUDT14 PCBD1 PNMA1 PNMA5 PPCDC PRMT1 PRPS2 PSME3 PTS PYGM RABAC1 RBBP8 RBPMS ROPN1 RPIA SEPTIN3 SFN SIAH1 SMN1 SSX2IP STX11 TCL1A THAP1 TLE5 TMEM239 TNR TOLLIP TRAF1 TRIM27 TRIM54 TRIP13 TSC22D1 VAC14 VCP XIAP ZBTB8A ZNF341
Entrez ID		5837	55093
HPRD ID		01986	07653
Ensembl ID		ENSG00000068976	ENSG00000156795
Uniprot IDs		P11217	A0A3B3ITD7 A0A3B3ITI2 E5RHC2 Q96HA8
PDB IDs		1Z8D	3C9Q 4W79
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?